Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Haptoglobin deficiency determines changes in adipocyte size and adipogenesis

Gamucci O., Lisi S., Scabia G., Marchi M., Piaggi P., Duranti E.

Laboratory Study on Type 2 Diabetes, published in Adipocyte (2012) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Adipocyte (2012)
Reported sample size
—
Source database
Europe PMC
PMID
23700523
PMCID
PMC3609090
DOI
10.4161/adip.20041
Citations
10

Abstract (original English)

Haptoglobin (Hp) is an inflammatory and adiposity marker, its expression during obesity being specifically induced in the white adipose tissue (WAT). We previously reported that when challenged with a high fat diet (HFD) Hp -/- mice are partially protected from the onset of insulin resistance and hepatosteatosis. The aim of the present study was to get further insights into Hp function in WAT. To this end, we performed histological and gene expression analysis of the Hp -/- WAT, both in standard and obesity conditions, and investigated how Hp deficiency impacts adipogenesis and WAT development. The average size and percentage of very large adipocytes were respectively smaller and reduced in HFD Hp -/- mice as compared with HFD WT. The expression of perilipin, HSL and angiogenesis related markers were increased in HFD Hp -/- mice. Lean adult Hp -/- showed significantly larger adipocytes and lower subcutaneous WAT expression of aP2 and LPL with respect to WT. Hp -/- young mice (P30) were characterized by larger adipocyte size and lower expression of adipocyte and adipogenesis markers. Comparison of adipocyte size distribution between young and adult mice revealed attenuated changes in Hp -/- mice compared with WT. Mouse embryonic fibroblasts from Hp -/- mice were less capable of accumulating triglycerides and exhibited lower expression of PPARγ , aP2 , FAS , LPL and Leptin . In c

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research